Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CLSA Cuts ALI HEALTH's TP to HKD5.3, Rating Outperform
Recommend 11 Positive 13 Negative 6 |
||||
|
||||
|
According to CLSA's report, ALI HEALTH (00241.HK) said at its 2HFY26 results outlook meeting that it maintained a solid revenue outlook but lowered its earnings expectations for investments in innovative drugs and AI technology. As its previous investment in the personal prescription drug segment was lower than that of its peers, ALI HEALTH is also stepping up investment to catch up, which may affect its gross profit growth trajectory this year. Its AI investment is aligned with its parent company's broader AI strategy. CLSA has reduced its target price for ALI HEALTH from HKD6 to HKD5.3 but kept the Outperform rating unchanged. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
